Pfizer wins $10B obesity drug takeover battle
Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.
Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.
Former President Donald Trump unveils ambitious strategy to dramatically reduce costs of groundbreaking weight-loss medications, promising relief for millions struggling with obesity.
Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giant to make obesity drugs more affordable and accessible across the United States.
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.
Pharmaceutical giant Eli Lilly reports explosive growth driven by Mounjaro and Zepbound, creating intense investor competition and reshaping the obesity treatment landscape.
Pharmaceutical giants and startups race to develop next-generation weight-loss treatments as demand soars and market valuations skyrocket in this healthcare revolution.
New Canadian research exposes the limitations of BMI, revealing millions with normal weight may have 'hidden obesity' and face serious health risks. Discover the silent epidemic your scale isn't showing you.